Attention AACR-NCI-EORTC Molecular Targets Conference Registrants - Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

Proffered Paper Session 1

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 6 of 6
Acquired resistance to RAF inhibitors is mediated by splicing isoforms of BRAF(V600E) that dimerize in a RAS-independent manner.
Poulikos I. Poulikakos
Memorial Sloan-Kettering Cancer Center, New York, NY, United States
from 2011 Molecular Targets and Cancer Therapeutics conference on November 13, 2011 4:30 PM-6:00 PM
KRAS mutation and amplification status predicts sensitivity to antifolate therapies in non small cell lung cancer
Sarah Bacus
Quintiles Transnational Corp., Westmont, IL, United States
from 2011 Molecular Targets and Cancer Therapeutics conference on November 13, 2011 4:30 PM-6:00 PM
Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: Association with clinical endpoints in a Phase II clinical trial of Pertuzumab and Erlotinib
Elizabeth Punnoose
Genentech, Inc., South San Francisco, CA, United States
from 2011 Molecular Targets and Cancer Therapeutics conference on November 13, 2011 4:30 PM-6:00 PM
Gene amplification of Anaplastic Lymphoma Kinase in Inflammatory Breast Cancer
Fredika M. Robertson
UT MD Anderson Cancer Ctr., Houston, TX, United States
from 2011 Molecular Targets and Cancer Therapeutics conference on November 13, 2011 4:30 PM-6:00 PM
GATA2 is required for oncogene-driven non-small cell lung cancer
MADHU S KUMAR
CRUK LONDON RESEARCH INSTITUTE, LONDON, United Kingdom
from 2011 Molecular Targets and Cancer Therapeutics conference on November 13, 2011 4:30 PM-6:00 PM
Pharmacodynamic analysis of ENCORE 301, a placebo controlled, randomized phase 2 study of exemestane with and without entinostat in postmenopausal ER+ breast cancer patients demonstrates an association of lysine hyperacetylation with clinical outcome
Peter Ordentlich
Syndax Pharmaceuticals, Inc., Waltham, MA, United States
from 2011 Molecular Targets and Cancer Therapeutics conference on November 13, 2011 4:30 PM-6:00 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 6 of 6